ArticleInternational journal of clinical pharmacy2026
Development and validation of a PD-L1 and tumor mutational burden-based predictive model for pathological complete response after neoadjuvant immunotherapy in resectable lung cancer.
Xiao Wu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.